---
permalink: /ai-powered-virtual-mtb/
title: "AI-Powered Virtual Tumor Board"
layout: single
author_profile: false
---

<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-EZ92F8GGBM"></script>
<script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'G-EZ92F8GGBM');
</script>

<style>
.hero-section {
  background: linear-gradient(135deg, #1e1b4b 0%, #312e81 100%);
  border-radius: 16px;
  padding: 3rem 2rem;
  text-align: center;
  margin-bottom: 2rem;
}
.hero-section h2 {
  color: #fff;
  font-size: 2rem;
  margin: 0 0 1rem 0;
}
.hero-tagline {
  color: #c7d2fe;
  font-size: 1.2rem;
  margin: 0;
}
.stat-grid {
  display: grid;
  grid-template-columns: repeat(3, 1fr);
  gap: 1.5rem;
  margin: 2rem 0;
}
.stat-card {
  background: linear-gradient(135deg, #1e293b 0%, #0f172a 100%);
  border: 1px solid #334155;
  border-radius: 12px;
  padding: 1.5rem;
  text-align: center;
}
.stat-number {
  font-size: 2.5rem;
  font-weight: 800;
  background: linear-gradient(135deg, #818cf8, #c084fc);
  -webkit-background-clip: text;
  -webkit-text-fill-color: transparent;
  background-clip: text;
}
.stat-label {
  font-size: 0.9rem;
  color: #94a3b8;
  margin-top: 0.5rem;
}
.personal-story {
  background: linear-gradient(135deg, #1e1b4b 0%, #312e81 100%);
  border-left: 4px solid #818cf8;
  border-radius: 0 12px 12px 0;
  padding: 1.5rem 2rem;
  margin: 2rem 0;
}
.personal-story h3 {
  color: #e0e7ff;
  margin-top: 0;
  font-size: 1.4rem;
}
.personal-story p {
  color: #f1f5f9;
  line-height: 1.7;
  margin-bottom: 1rem;
}
.personal-story em {
  color: #fbbf24;
  font-style: italic;
}
.personal-story strong {
  color: #ffffff;
  font-weight: 700;
}
.value-prop {
  background: linear-gradient(135deg, #0f172a 0%, #1e293b 100%);
  border: 2px solid #334155;
  border-radius: 12px;
  padding: 2rem;
  margin: 2rem 0;
}
.value-prop h3 {
  color: #f1f5f9;
  margin-top: 0;
}
.value-prop ul {
  color: #cbd5e1;
  line-height: 1.8;
}
.value-prop li {
  margin-bottom: 0.5rem;
}
.cta-section {
  background: linear-gradient(135deg, #6366f1 0%, #8b5cf6 100%);
  border-radius: 16px;
  padding: 2.5rem;
  text-align: center;
  margin: 3rem 0;
}
.cta-section h3 {
  color: #fff;
  font-size: 1.5rem;
  margin: 0 0 1rem 0;
}
.cta-section p {
  color: #e0e7ff;
  margin: 0 0 1.5rem 0;
  font-size: 1.1rem;
}
.cta-button {
  display: inline-flex;
  align-items: center;
  gap: 0.5rem;
  padding: 1rem 2rem;
  background: #fff;
  color: #4f46e5;
  font-weight: 700;
  font-size: 1.1rem;
  border-radius: 8px;
  text-decoration: none;
  transition: transform 0.2s, box-shadow 0.2s;
}
.cta-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 10px 30px rgba(0,0,0,0.2);
  color: #4f46e5;
  text-decoration: none;
}
.audience-grid {
  display: grid;
  grid-template-columns: repeat(2, 1fr);
  gap: 1.5rem;
  margin: 2rem 0;
}
.audience-card {
  background: #1e293b;
  border: 1px solid #334155;
  border-radius: 12px;
  padding: 1.5rem;
}
.audience-card h4 {
  color: #f1f5f9;
  margin: 0 0 0.75rem 0;
  display: flex;
  align-items: center;
  gap: 0.5rem;
}
.audience-card p {
  color: #94a3b8;
  margin: 0;
  font-size: 0.9rem;
  line-height: 1.6;
}
@media (max-width: 768px) {
  .stat-grid, .audience-grid {
    grid-template-columns: 1fr;
  }
}
</style>

<div class="hero-section">
  <h2>AI-Powered Virtual Tumor Board</h2>
  <p class="hero-tagline">Democratizing Expert Cancer Care Through Multi-Agent AI</p>
</div>

## The Problem: Tumor Boards Save Lives, But Most Patients Never Get One

A **Multidisciplinary Tumor Board (MTB)** is a meeting where oncologists from different specialties—surgery, medical oncology, radiation, pathology, radiology, genetics, and palliative care—gather to discuss complex cancer cases and reach a consensus treatment plan.

**The evidence is clear**: MTB discussions improve cancer outcomes, reduce treatment delays, and ensure patients get guideline-concordant care.

<div class="stat-grid">
  <div class="stat-card">
    <div class="stat-number">&lt;5%</div>
    <div class="stat-label">of Indian cancer patients get MTB review</div>
  </div>
  <div class="stat-card">
    <div class="stat-number">1.4M</div>
    <div class="stat-label">new cancer cases in India yearly</div>
  </div>
  <div class="stat-card">
    <div class="stat-number">~800</div>
    <div class="stat-label">oncologists per 100,000 patients (US has 3,000+)</div>
  </div>
</div>

**Why don't more patients get tumor boards?**
- Severe oncologist shortage, especially outside metros
- Time constraints—a single MTB meeting takes 1-2 hours
- Coordination challenges across specialties
- No reimbursement for MTB participation in most settings

---

<div class="personal-story">
  <h3>Why I Built This</h3>
  
  <p>Last year, my aunt was diagnosed with cancer. During staging, her MRI showed a lesion in her vertebra. The radiologist's report was ambiguous: <em>"sclerotic change, possibly age-related, cannot rule out metastatic disease."</em></p>
  
  <p>That single sentence was the difference between Stage II (curable) and Stage IV (incurable).</p>
  
  <p>We were fortunate. Through family connections, we got her case reviewed at a tumor board with some of India's best oncologists. After careful review, they concluded it was a benign age-related change. She received curative-intent treatment.</p>
  
  <p><strong>Most Indian cancer patients don't have that privilege.</strong> They don't have connections to top oncologists. They can't travel to metros. They can't afford private consultations with 7 specialists.</p>
  
  <p>I'm building the AI Virtual Tumor Board to democratize access to expert-level multidisciplinary deliberation.</p>
</div>

---

## The Solution

A proprietary AI system that simulates comprehensive tumor board deliberation with **multiple specialist agents** covering:

- Surgical Oncology
- Medical Oncology  
- Radiation Oncology
- Palliative Care
- Radiology
- Pathology
- Genetics/Genomics

The system produces **structured, guideline-grounded treatment recommendations** with citations to NCCN, ESMO, ASTRO, and other authoritative sources—while being aware of **Indian healthcare context** including drug availability, costs, and insurance coverage.

<div class="value-prop">
  <h3>Key Differentiators</h3>
  <ul>
    <li><strong>True Multi-Agent Deliberation</strong> — Not a single chatbot, but specialized agents that debate and reach consensus</li>
    <li><strong>Adversarial Safety Architecture</strong> — Built-in mechanisms to catch errors and prevent hallucinations</li>
    <li><strong>Guideline-Grounded</strong> — Every recommendation citable to clinical guidelines</li>
    <li><strong>India-Aware</strong> — Considers DCGI approvals, INR costs, Ayushman Bharat coverage</li>
    <li><strong>Multimodal</strong> — Can incorporate imaging and pathology data</li>
  </ul>
</div>

---

## Who This Is For

<div class="audience-grid">
  <div class="audience-card">
    <h4>🏥 Hospital Oncology Departments</h4>
    <p>Augment your tumor board capacity. Handle more cases with consistent quality. Reduce time-to-treatment-decision for routine cases while freeing up expert bandwidth for complex ones.</p>
  </div>
  <div class="audience-card">
    <h4>👨‍⚕️ Community Oncologists</h4>
    <p>Get second-opinion-level deliberation for your patients without referral delays. Especially valuable in tier-2/tier-3 cities with limited specialist access.</p>
  </div>
  <div class="audience-card">
    <h4>🏛️ Healthcare Systems & CMIOs</h4>
    <p>Standardize care quality across your network. Ensure guideline concordance. Generate structured documentation. Reduce variability in treatment planning.</p>
  </div>
  <div class="audience-card">
    <h4>💼 Investors</h4>
    <p>Precision oncology market growing rapidly. AI in healthcare is at an inflection point. First-mover opportunity in India's 1.4M annual cancer cases.</p>
  </div>
</div>

---

## Current Status

- **Working prototype** with multi-agent deliberation
- **Evaluated on synthetic cases** — seeking clinical validation partnerships
- **Pre-seed stage** — actively exploring fundraising

<div style="background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%); border: 2px solid #f59e0b; border-radius: 12px; padding: 1.25rem; margin: 2rem 0;">
  <p style="color: #78350f; margin: 0; font-size: 0.95rem; line-height: 1.6;">
    <strong style="color: #92400e;">Research Stage:</strong> This is early-stage work evaluated only on synthetic cases. All performance metrics are design goals, not validated results. We are actively seeking clinical validation partnerships with oncology departments.
  </p>
</div>

---

<div class="cta-section">
  <h3>Let's Talk</h3>
  <p>Interested in piloting, partnering, or investing? I'd love to hear from you.</p>
  <a href="mailto:spiff007@gmail.com?subject=Virtual%20Tumor%20Board%20-%20Interest" class="cta-button">
    <svg width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M4 4h16c1.1 0 2 .9 2 2v12c0 1.1-.9 2-2 2H4c-1.1 0-2-.9-2-2V6c0-1.1.9-2 2-2z"></path><polyline points="22,6 12,13 2,6"></polyline></svg>
    Contact Me
  </a>
</div>

<div style="text-align: center; margin-top: 1rem;">
  <p style="color: #64748b; font-size: 0.9rem;">
    Or connect on <a href="https://twitter.com/inventcures" style="color: #818cf8;">Twitter/X</a> · <a href="https://linkedin.com/in/tp53" style="color: #818cf8;">LinkedIn</a>
  </p>
</div>

---

<div style="background: #1e293b; border: 1px solid #475569; border-radius: 8px; padding: 1.25rem; margin-top: 3rem;">
  <p style="text-align: center; color: #94a3b8; font-size: 0.85rem; margin: 0; line-height: 1.6;">
    <strong style="color: #f1f5f9;">Disclaimer:</strong> This is a research prototype. AI-generated recommendations must always be verified by qualified oncologists. Not intended for clinical decision-making without physician oversight.
  </p>
</div>
